Press Releases

CHICAGO, Dec. 4 /PRNewswire-FirstCall/ -- PrivateBancorp, Inc. (Nasdaq: PVTB) announced today its board of directors declared a quarterly cash dividend of $0.01 per share for the fourth quarter 2009 payable on December 31, 2009, to stockholders of record on December 17, 2009. This dividend is unchanged from the prior quarterly dividend of $0.01 per share.

SOURCE PrivateBancorp, Inc.

AUSTIN, Texas--(BUSINESS WIRE)-- Forestar Group Inc. (NYSE: FOR) today announced that Jim DeCosmo, president and chief executive officer, will be presenting at the Bank of America Merrill Lynch Global Industries Conference in New York City on Tuesday December 8, 2009 at 2:30 pm EST.

The live presentation may be accessed through Forestar Group's Internet site, www.forestargroup.com, by clicking on "Investor Relations - Investor Events." Replays of the presentation will be available for two weeks following completion of the live presentation.

About Forestar Group

Forestar Group Inc. operates in three business segments: real estate, mineral resources and fiber resources. The real estate segment owns directly or through ventures over 255,000 acres of real estate located in nine states and twelve markets in the U.S. The real estate segment has 21 real estate projects representing over 31,500 acres currently in the entitlement process, and 75 entitled, developed and under development projects in seven states and eleven markets encompassing over 16,000 acres, comprised of over 29,600 residential lots and over 2,300 commercial acres. The mineral resources segment manages about 622,000 net acres of oil and gas mineral interests. The fiber resources segment include the sale of wood fiber and management of our recreational leases. The company also has a 45% nonparticipating royalty interest in groundwater produced or withdrawn for commercial purposes from approximately 1.38 million acres in Texas, Louisiana, Georgia and Alabama. Forestar's address on the World Wide Web is www.forestargroup.com.

Forward-looking Statements

This release contains "forward-looking statements" within the meaning of the federal securities laws. These statements reflect management's current views with respect to future events and are subject to risk and uncertainties. We note that a variety of factors and uncertainties could cause our actual results to differ significantly from the results discussed in the forward-looking statements. Factors and uncertainties that might cause such differences include, but are not limited to: general economic, market, or business conditions; the opportunities (or lack thereof) that may be presented to us and that we may pursue; fluctuations in costs and expenses including development costs; demand for new housing, including impacts from mortgage credit availability; lengthy and uncertain entitlement processes; cyclicality of our businesses; accuracy of accounting assumptions; competitive actions by other companies; changes in laws or regulations; and other factors, many of which are beyond our control. Except as required by law, we expressly disclaim any obligation to publicly revise any forward-looking statements contained in this news release to reflect the occurrence of events after the date of this news release.

    Source: Forestar Group Inc.

INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

The updated Zyprexa label states that clinicians should take into consideration the increased potential for weight gain and hyperlipidemia in adolescents compared to adults and the potential for long-term risks, which in many cases, may lead them to consider prescribing other drugs first in adolescents. Compared to patients from adult clinical trials, adolescents were also likely to experience increased sedation and greater increases in prolactin levels and hepatic transaminase (liver enzymes) levels. The recommended starting dose for adolescents is lower than that for adults.

An FDA Psychopharmacologic Drug Advisory Committee (PDAC) met in June and discussed the difficulties of diagnosing and treating these conditions in adolescents. The Zyprexa label provides additional guidance to physicians that medication therapy for pediatric schizophrenia or bipolar I disorder should be initiated only after a thorough diagnostic evaluation and careful consideration of the risks associated with medication treatment.

The updated Zyprexa label also highlights the need for a comprehensive treatment program in pediatric patients and recommends that Zyprexa be used as part of a "total treatment program for pediatric patients with schizophrenia and bipolar I disorder," which may include psychological, educational and social interventions.

This approval follows a favorable vote regarding the safety and efficacy of Zyprexa from the FDA PDAC in June on Lilly's supplemental New Drug Applications for these indications. The Committee examined findings from two pivotal clinical trials: one six-week trial in adolescents with schizophrenia and one three-week trial in adolescents with manic or mixed episodes associated with bipolar I disorder, as well as extensive Zyprexa safety data relevant to adolescents.

"There has been a recognized need in the mental health community for additional guidance on treating teens diagnosed with these serious mental illnesses," said Cherri Miner, M.D., Lilly USA Neuroscience Senior Medical Director. "Customers have been asking for data from controlled studies in these populations, and now with this information added to our label, we can help physicians make informed treatment decisions."

About Schizophrenia in Adolescents

Schizophrenia affects about 1 percent of Americans.(1) A substantial portion of first psychotic breaks for schizophrenia occur in adolescence. It has been estimated that 39 percent of males and 23 percent of females with schizophrenia experience onset of the disease before the age of 19.(2) Studies have suggested that early-onset schizophrenia is associated with worse long-term outcomes compared to onset of illness in adulthood.(3)

About Bipolar Disorder in Adolescents

Bipolar disorder affects approximately 5.7 million American adults, or about 2.6 percent of the U.S. population age 18 and older, in a given year.(4) It has an estimated prevalence of 0.1 percent to 2 percent among adolescents.(5) Lifetime prevalence of bipolar I disorder in community samples has varied from 0.4 percent to 1.6 percent.(6) It has been estimated that 20 percent of all patients with bipolar disorder experience their first episode during adolescence, with the peak age of onset for this group of patients occurring between 15 and 19 years of age.(7) Early onset of bipolar disorder is associated with greater severity of illness and more functional impairment.(8)

Safety Information for Zyprexa (olanzapine)

Zyprexa is indicated in adults in the United States for the treatment of schizophrenia, acute treatment of mixed and manic episodes of bipolar I disorder, and maintenance treatment of bipolar I disorder.

Zyprexa is indicated for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents 13 to 17 years of age. When deciding among alternative treatments available for adolescents, clinicians should consider the increased potential for weight gain and hyperlipidemia compared to adults. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead clinicians to consider prescribing other drugs first in adolescents.

Olanzapine is not approved for the treatment of patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

In addition, compared to elderly patients with dementia-related psychosis taking a placebo, there was a significantly higher incidence of cerebrovascular adverse events (e.g. stroke, transient ischemic attack) in elderly patients with dementia-related psychosis treated with olanzapine.

The possibility of a suicide attempt is inherent in schizophrenia and bipolar I disorder. Close supervision of high-risk patient should accompany drug therapy.

As with all antipsychotic medications, a rare and potentially fatal condition known as Neuroleptic Malignant Syndrome (NMS) has been reported with olanzapine. If signs and symptoms appear, immediate discontinuation is recommended. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

Hyperglycemia, in some cases associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics, including olanzapine. While relative risk estimates are inconsistent, the association between atypical antipsychotics and increases in glucose levels appears to fall on a continuum and olanzapine appears to have a greater association than some other atypical antipsychotics. Physicians should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus, or having borderline increased blood glucose level. Patients taking olanzapine should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, palyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing.

Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using olanzapine, is advised. Clinically significant, and sometimes very high, elevations in triglyceride levels and modest mean elevations in total cholesterol have been observed with olanzapine use.

Potential consequences of weight gain should be considered prior to starting olanzapine. Patients receiving olanzapine should receive regular monitoring of weight.

Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize Tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Olanzapine may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia, and in some patients, syncope, especially during the initial dose-titration period. Particular caution should be used in patients with known cardiovascular disease, cerebrovascular diseases, or those predisposed to hypotension.

Other potentially serious adverse events include decreased white blood cell count (leukopenia, neutropenia, agranulocytosis), seizures, elevated prolactin levels, cognitive and motor impairment, body temperature elevation, and trouble swallowing.

The recommended starting dose for adolescents is lower than that for adults. Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels. When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential for weight gain and hyperlipidemia compared to adults. Clinicians should consider the long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents. Medication treatment for adolescent schizophrenia and bipolar I disorder should be initiated only after a thorough diagnostic evaluation and careful consideration of the risks associated with medication treatment. Medication treatment for both adolescent schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions. Safety and effectiveness of olanzapine in patients <13 years of age have not been established.

The most common treatment-emergent adverse event associated with oral Zyprexa in placebo-controlled, short-term schizophrenia and bipolar mania trials in adults was somnolence. Other common events were dizziness, weight gain, personality disorder (COSTART term for nonaggressive objectionable behavior), constipation, akathisia, postural hypotension, dry mouth, asthenia, dyspepsia, increased appetite and tremor.

The most common treatment-emergent adverse events associated with oral olanzapine (vs placebo) in clinical trials of adolescents (13-17 years old) were sedation (44% vs 9%), weight increased (30% vs 6%), increased appetite (24% vs 6%), headache (17% vs 12%), fatigue (9% vs 4%), liver enzymes increased (8% vs 1%), dizziness (7% vs 2%), dry mouth (6% vs 0%), pain in extremity (5% vs 1%).

Full prescribing information, including boxed warning, and medication guide are available at www.zyprexa.com.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

Zyprexa® (olanzapine, Lilly)

P-LLY

This press release contains forward-looking statements about Zyprexa. These statements reflect management's current beliefs; however, as with any pharmaceutical product there are risks and uncertainties in the process of research and development, regulatory review and commercialization. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(1) The National Institute of Mental Health. What is Schizophrenia? Available at: http://www.nimh.nih.gov/health/publications/schizophrenia/what-is-schizophrenia.shtml. Accessed November 20, 2009.

(2) Loranger, AW. (1984). Sex Difference in Age of Onset of Schizophrenia. Archives of General Psychiatry; 41:157-161.

(3) Fleischhaker, C. et al. (2005). Long-term Course of Adolescent Schizophrenia. Schizophrenia Bulletin; 31(3):769-780.

(4) Kessler RC, Chiu WT, Demler O, Walters EE. (2005). Prevalence, Severity, and Comorbidity of Twelve-month DSM-IV Disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, Jun; 62(6):617-27.

(5) Mauricio Tohen et al. (2007). Olanzapine versus Placebo in the Treatment of Adolescents with Bipolar Mania. American Journal of Psychiatry, 164: 1547-1556.

(6) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, pg. 385.

(7) McClellan, J. and Werry, J. (1997). Practice Parameters for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 36(1):138-157.

(8) Axelson D et al. (2006). Phenomenology of children and adolescents with bipolar spectrum disorders. Archives of General Psychiatry; 63(10):1139-48.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

PEMBROKE, Bermuda, Dec. 4 /PRNewswire-FirstCall/ -- Allied World Assurance Company Holdings, Ltd (NYSE: AWH) today announced that Scott Carmilani, President and Chief Executive Officer, and Jack Sennott, Executive Vice President and Chief Corporate Strategy Officer, will be presenting at the 2009 Goldman Sachs U.S. Financial Services Conference being held at the Goldman Sachs Conference Center in New York City on Tuesday, December 8, 2009.

About Allied World Assurance Company

Allied World Assurance Company Holdings, Ltd, through its subsidiaries, is a global provider of innovative property, casualty and specialty insurance and reinsurance solutions, offering superior client service through offices in Bermuda, the United States, Europe, Hong Kong and Singapore. Our insurance and reinsurance subsidiaries are rated A (Excellent) by A.M. Best Company. For further information on Allied World, please visit our website at www.awac.com.

Cautionary Statement Regarding Forward-Looking Statements

Any forward-looking statements made in this press release reflect our current views with respect to future events and financial performance and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, which may cause actual results to differ materially from those set forth in these statements. For example, our forward-looking statements could be affected by the ability to recognize the benefits of the Darwin Professional Underwriters, Inc. acquisition; pricing and policy term trends; increased competition; the impact of acts of terrorism and acts of war; greater frequency or severity of unpredictable catastrophic events; investigations of market practices and related settlement terms; negative rating agency actions; the adequacy of our loss reserves; the company or its subsidiaries becoming subject to significant income taxes in the United States or elsewhere; changes in regulations or tax laws; changes in the availability, cost or quality of reinsurance or retrocessional coverage; adverse general economic conditions including those related to the ongoing financial crisis; and judicial, legislative, political and other governmental developments, as well as management's response to these factors, and other factors identified in our filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We are under no obligation (and expressly disclaim any such obligation) to update or revise any forward-looking statement that may be made from time to time, whether as a result of new information, future developments or otherwise.

http://www.awac.com

SOURCE Allied World Assurance Company Holdings, Ltd

    1.  Behavior: All Men Don't Have to Be Like Tiger Woods
    2.  Family Issues: TV's Impact on Teen Pregnancy
    3.  Health: Cosmetic Procedure Tax is Short-Sighted and Discriminative
    4.  Home: Eco-Friendly Living Can Be Easy Indoors and Out
    5.  Relationships: Tiger Woods' Scandal and Relationship

1. BEHAVIOR: ALL MEN DON'T HAVE TO BE LIKE TIGER WOODS. BRAD STEVENSON is the co-founder of TRANS-WORLD DYNAMICS (TWD) and PATHFINDERS, a program for men's self-discovery and personal empowerment, based in Albuquerque, N.M. He has devoted his life to helping men change, and is an expert in guiding men: "High-profile men in the media, like Tiger Woods, who cheat on their wives perpetuate the idea 'that's just what men do' and that this type of behavior is just part of men's character. However, there's no reason to accept that this is just what men do, and there's a whole movement out there that's helping men to change this negative, self-destructive behavior." Stevenson is available to discuss how men are typically viewed, the psychological effect of this stereotype and how to embrace one's true self for greater success in life. As part of Trans-World Dynamics, Stevenson has created unique workshops, seminars and programs that provide people with the opportunity to find and unlock their passion and purpose in order to excel both personally and professionally. News Contact: Briana Samuels, publicrelations@businessdevelopmentgroup.com Phone: +1-516-222-0236 (12/4/09)

2. FAMILY ISSUES: TV'S IMPACT ON TEEN PREGNANCY. KRIS FAASSE, director of adoption services for BETHANY CHRISTIAN SERVICES, the nation's largest adoption agency: "As teen birth rates are again rising (they had fallen for a number of years and just started rising again in 2006), the debut of MTV's 'Teen Moms' gives viewers an intimate glimpse into the challenges that young women face in raising a child. As a spinoff of the popular '16 & Pregnant' series, which was the No. 1 show for women 12-34, 'Teen Moms' will follow four young women in their teens as they navigate the bumpy terrain of adolescence and coming of age -- all while facing the responsibilities of parenting. Judging from the calls that we received, '16 & Pregnant' had a significant impact on many viewers, both currently pregnant and those who had made adoption plans in the past, by showing adoption as a positive option." Faasse can offer insight on the message these programs deliver regarding teen pregnancy and the impact they have on pregnant teenagers considering parenting their child on their own or making an adoption plan. Faasse is located in Grand Rapids, Mich. News Contact: Joe DiBenedetto, jdibenedetto@lambert- edwards.com Phone: +1-616-233-0500 Web site: http://www.bethany.org (12/4/09)

3. HEALTH: COSMETIC PROCEDURE TAX IS SHORTSIGHTED AND DISCRIMINATIVE. DR. JEFFREY EPSTEIN, world-renowned facial plastic and reconstructive surgeon, director and founder of the FOUNDATION FOR HAIR RESTORATION AND PLASTIC SURGERY, past president of the Florida Society of Facial Plastic and Reconstructive Surgery and noted as one of the top 25 U.S. facial plastic surgeons, can comment on the tax on cosmetic procedures in the proposed Senate health reform bill: "The proposed tax is short-sighted and arbitrarily discriminative to those who choose to improve their self-esteem and appearance through undergoing cosmetic surgery, and besides, is it really the government's job to decide which services are elective for my patients? If the goal of a tax is to both raise money while influencing behavior, why not create a federal tax on fast-food restaurants whose services have proven to be a burden on society with increased obesity, heart disease and diabetes?" Epstein can provide compelling perspective on the tax as a misdirected effort with the potential to negatively impact patients across the country seeking to improve their self-esteem and quality of life through the transformative power of plastic surgery and cosmetic procedures. Epstein is located in Miami and is fluent in Spanish. News Contact: Naomi Goldman, naomigoldman@hotmail.com Phone: +1-310-770-2765 (12/2/09)

4. HOME: ECO-FRIENDLY LIVING CAN BE EASY INDOORS AND OUT. SARAH BARNARD, green interior designer, LEED-accredited professional and building biology practitioner: "The essential aim of sustainable design is to create places and spaces that reduce the use of non-renewable resources and minimize environmental impact. Simple steps you take at home can make a major impact on indoor air quality, save the landfills and drastically reduce water and energy use." Barnard undertakes a broad range of projects, all of which are grounded in smart design and mindful of healthy living. She can discuss sustainable and healthy living for everyone and provide easy-to-implement green-living tips. Barnard is located in Los Angeles. Web site: http://www.sarahbarnard.com (12/4/09)

5. RELATIONSHIPS: TIGER WOODS' SCANDAL AND RELATIONSHIP. MICHAEL D. ZENTMAN, Ph.D., director of the ADELPHI UNIVERSITY postgraduate program in marriage and couple therapy in Garden City, N.Y.: "Cheating is not based on an individual's attractiveness, so being 'a gorgeous supermodel wife' would not offer Elin Woods any more protection from a disloyal partner than the rest of us. Most affairs occur when a marital relationship devolves into a state of emotional vulnerability. Like the human body, when a relationship is sufficiently weakened, it loses the benefit of an emotional immune system: The emotional bonds and attachments that help us to remain involved, instead of becoming detached. The risk of boundary violation occurs when a couple drifts too far apart." Zentman has been a practitioner in the field of psychology for more than 30 years and has taught at the graduate and post-doctoral level for more than 15 years. He is certified in psychoanalysis and psychotherapy, group therapy and family and marital therapy. Zentman treats adults, adolescents, couples and families. He specializes in intensive individual therapy and treating highly distressed couples. He has extensive media experience with Newsday, WebMD.com and NBC's "Today in New York," among others. News Contact: Kali Chan, chan@adelphi.edu Cell: +1-631-521-5513 (12/4/09)

PROFNET is an exclusive service of PR Newswire. To submit an Opportunity by e-mail: profnet@profnet.com To consult the ProfNet Experts Database: http://www.prnewswire.com/profnet To contact ProfNet by phone: +1-800-PROFNET, ext. 1 To share a thought on ProfNet Expert Alerts: profnetalerts@prnewswire.com

SOURCE ProfNet